Literature DB >> 6189106

Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.

S Rannikko, H Adlercreutz.   

Abstract

The nature of hormonal changes with age and the possible role of these changes in the development of benign prostatic hyperplasia (BPH) and prostatic cancer (PC) were studied by assaying the plasma levels of total and free testosterone (T), estradiol (E2), prolactin, and sex hormone binding globulin binding capacity (SHBG) in 20 normal healthy men aged 40-59 years, in 30 patients with BPH aged 63-79 years, and in 30 patients with PC of similar height, weight, and age as the BPH patients. The mean E2 was highly significantly (P less than 0.0005) lower in the PC patients and in the young controls than in the BPH patients. The mean free T was significantly higher in the young controls than in the BPH patients (P less than 0.025) and PC patients (P less than 0.0005). The PC patients had a slightly lower (P less than 0.05) mean free T and mean E2/free T ratio than the BPH patients. The mean E2/free T ratio was significantly higher in the BPH patients (P less than 0.0005) and in the PC patients (P less than 0.0025) than in the young controls. It seems possible that the observed age-dependent significant increase in plasma estrogen concentration in the BPH patients may act as a protective factor against prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189106     DOI: 10.1002/pros.2990040302

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Complementary medicine for prostate cancer: effects of soy and fat consumption.

Authors:  M A Moyad; W A Sakr; D Hirano; G J Miller
Journal:  Rev Urol       Date:  2001

3.  Endogenous testosterone as a predictor of prostate growing disorders in the aging male.

Authors:  Antonio Benito Porcaro; Nelia Amigoni; Alessandro Tafuri; Riccardo Rizzetto; Aliasger Shakir; Leone Tiso; Clara Cerrato; Vincenzo Lacola; Stefano Zecchini Antoniolli; Alessandra Gozzo; Katia Odorizzi; Matteo Brunelli; Filippo Migliorini; Walter Artibani; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

Review 4.  Prolactin regulation of the prostate gland: a female player in a male game.

Authors:  Vincent Goffin; David T Hoang; Roman L Bogorad; Marja T Nevalainen
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

5.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

6.  Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.

Authors:  Bo Sung Shin; Eu Chang Hwang; Chang Min Im; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Korean J Urol       Date:  2010-12-21

7.  Do prostate-specific antigen parameters have a similar role in predicting prostate cancer regardless of serum testosterone levels in men with gray-zone prostate-specific antigen levels?

Authors:  Jeong Hoon Oh; Ho Seok Chung; Myung Soo Kim; Eu Chang Hwang; Seung Il Jung; Dongdeuk Kwon; Kwangsung Park
Journal:  Transl Androl Urol       Date:  2022-04

8.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.